Research Study

A Phase 2b, Multicenter, Randomized, Open-label Study to Investigate the Efficacy, Safety and Pharmacokinetics of Different Treatment Regimens of AL-335, Odalasvir, and Simeprevir in Treatment-naive and Treatment-experienced Subjects With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5, and 6 Infection Without Cirrhosis
Principal Investigator 
Eric M. Yoshida

Overview

Body Locations and Systems 
Hepatitis C
ClinicalTrials.gov# 
NCT02765490
Status 
Recruiting
Study Start/End 
Oct 31, 2016 to Nov 1, 2017
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Jo-Ann Ford, Research Coordinator
Phone 
604-875-5705
Email Address 
joann.ford@vch.ca
Purpose of Study 

The purpose of this study is to evaluate the efficacy (proportion of subjects with SVR12), safety, tolerability and pharmacokinetics of an 8- and 6-week treatment regimen of AL-335, odalasvir (ODV) and simeprevir (SMV) in chronic HCV genotype 1, 2, 4, 5 or 6 infected subjects without cirrhosis.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.